Trial Profile
A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2022
Price :
$35
*
At a glance
- Drugs Tadnersen (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; First in man
- Sponsors Biogen
- 28 Mar 2022 According to Biogen media release, Biogen and Ionis will present this study data at a future scientific forum.
- 28 Mar 2022 Results published in the Media Release
- 28 Mar 2022 Status has been changed to discontinued, according to Biogen media release.